NCT05768334View on ClinicalTrials.gov

Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease

PHASE3CompletedINTERVENTIONAL

Enrollment

116

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

February 1, 2023

Study Completion Date

February 1, 2023

Conditions

NAFLD

Interventions

DRUG

Lubiprostone 24Mcg Oral twice daily

"The patients will be randomized (closed envelopes) into one of two groups:~1. Fifty patients will receive lubiprostone 24 mcg (microgram) twice daily.~2. Fifty patients will receive placebo twice daily (control group). All patients will be followed for 48 weeks."

Trial Locations (1)

Unknown

National Hepatology and Tropical Medicine Research Institute, Cairo

All Listed Sponsors

lead

Helwan University

OTHER

NCT05768334 - Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease | Biotech Hunter | Biotech Hunter